A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours
Gabriel Mak(Sarah Cannon Research Institute), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Alastair Greystoke(Newcastle University), Jean‐Charles Soria(Inserm), Anas Gazzah(Institut Gustave Roussy), Ruth Plummer(National Health Service), Debra Rogan(Research Triangle Park Foundation), Jolly Mazumdar(Howard Hughes Medical Institute), Sarah P. Blagden(Churchill Hospital), Noelia Nebot(Research Triangle Park Foundation), Jianping Zhang(Fujian Medical University), Li Yan(Research Triangle Park Foundation), Jerry M. Tolson(Research Triangle Park Foundation), Kurt R. Auger(Research Triangle Park Foundation), Ronald A. Fleming(Research Triangle Park Foundation), Ivana Rizzuto(Imperial College Healthcare NHS Trust)
Cited by 103
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2015|664